Abstract.
The association between central lymph node metastasis (LNM) and risk factors, including the presence of the BRAF mutation, BRAF V600E , in patients with papillary thyroid cancer (PTC) requires further investigation. A potent risk factor that can indicate LNM in different histological subtypes of PTC and in different preoperative central lymph node statuses also requires further research. A total of 287 patients with PTC who accepted thyroidectomy were included in the present study. Clinicopathological data of these patients were reviewed to examine the risk factors for central LNM through univariate and multivariate analyses. Overall, BRAF V600E in patients with cN0 (subclinical nodal disease) and cN1 (other than cN0) PTC was associated with central LNM. However, multivariate analyses demonstrated that BRAF V600E was not an independent risk factor in patients with cN1 or cN0 PTC. For patients with classical variant PTC (CVPTC), BRAF V600E was independently associated with central LNM. However, on further analysis, the association was only significant in patients with cN0 CVPTC. For patients with follicular variant PTC (FVPTC) or aggressive variant PTC (AVPTC), the BRAF V600E mutation rate was not significantly different between patients with and without central LNM. In conclusion, BRAF V600E was an independent risk factor for central LNM overall in patients with PTC and in patients with CVPTC, particularly in patients with cN0 CVPTC. However, BRAF V600E was not an independent risk factor for patients with FVPTC and AVPTC. Therefore, BRAF V600E provides varied clinical significance in different histological subtypes and preoperative central lymph node status.
Introduction
Thyroid cancer is the most common endocrine system malignancy and accounts for ~1% of all cancer diagnoses, with an incidence that increases each year (1) . Among thyroid malignancies, papillary thyroid cancer (PTC) is the most common histological type, accounting for 80-85% of all thyroid cancer and presenting with a 10-year survival rate of >90% (2) . PTC is not a unitary carcinoma; this malignancy includes several sub-histological variants, including classical variant PTC (CVPTC) and follicular variant PTC (FVPTC). Tall cell, diffuse sclerosing and poorly differentiated PTC subtypes are categorized as aggressive variant PTC (AVPTC). Although patients with PTC typically demonstrate an excellent prognosis, cervical lymph node metastasis (LNM) can be identified in 40-90% of cases at the time of the first surgery (3) . The most typical LNM site is the central neck compartment (level VI). LNM has been confirmed to be an independent risk factor for regional recurrence (4) (5) (6) and decreased survival (7) (8) (9) . The American Joint Committee on Cancer advocates the surgical removal of suspected lymph nodes detected by preoperative ultrasonography (10) . However, a routine central neck lymph node dissection (LND) in patients with subclinical nodal disease (cN0) is controversial. On one hand, LNM occurs in 60% of patients with PTC BRAF V600E mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account on average (11) and metastasis has been reported in ≤50% of dissected lymph nodes in cN0 patients (12) . Prophylactic LND can remove subclinical metastatic lymph nodes, thus avoiding potential recurrence in addition to aiding in disease staging for radioiodine therapy (4, 13) . On the other hand, previous studies have reported that prophylactic LND in cN0 patients increases the rate of recurrent laryngeal nerve injury and hypoparathyroidism, which would be disadvantageous for patients with PTC (14, 15) . The T1799A nucleotide transversion in the B-Raf proto-oncogene (BRAF) gene (NM_004333) causes a V600E amino acid substitution and leads to constitutive activation of the mitogen-activated protein kinase signaling pathway (16) . Previous studies have demonstrated that BRAF V600E is the most frequent genetic change in PTC, with prevalence ranging from 27 to 83% (17, 18) . The association between BRAF V600E and central LNM has been widely investigated. The majority of studies support that BRAF V600E is associated with the presence of LNM and the probability of recurrence (18) (19) (20) . Certain studies considered that patients with the BRAF V600E mutation should receive LND in the central compartment (18, 21, 22) . However, other studies reported that the correlation between BRAF V600E and tumor aggressiveness, involving LNM, was not evident (23, 24) . Thus, this divergence in the association between BRAF V600E and more aggressive clinicopathological characteristics deserves further in-depth investigation.
To date, to the best of our knowledge, just one previous study has investigated the clinical significance of BRAF V600E for central LNM based on preoperative central lymph node status and various histological subtypes of PTC (25) . Therefore, the present study was designed to separately assess the clinical significance of BRAF V600E in patients with cN0 and cN1 PTC with different histological subtypes.
Patients and methods

Patients.
A total of 793 patients accepted thyroidectomy in Department of Surgical Oncology of the First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China) between January 2007 and April 2011. These patients were diagnosed with PTC during the final pathological examination. All patients came from the eastern coastal regions in China. Eligibility criteria were as follows: Patients' acceptance of total thyroidectomy plus central LND, absence of a history of neck surgery or radiotherapy on the thyroid, and absence of other types of head and neck cancer. A total of 397 patients were excluded from the present study as they only underwent thyroidectomy, 93 were disqualified for having a previous history of neck surgery or radiotherapy on the thyroid gland, and another 16 were omitted for their history of other types of head and neck cancer. Finally, 287 patients with PTC with total thyroidectomy plus central LND were enrolled. Clinicopathological data included patients' age at diagnosis, sex, tumor size, Hashimoto's thyroiditis, multifocality, extrathyroidal extension, thyroid capsular invasion, central LNM and tumor histological subtype. If >1 malignant nodule existed in the thyroid gland, the largest nodule was analyzed. cN0 patients were those patients without preoperative clinical or ultrasonic evidence of central LNM and without suspicious lymph nodes identified during surgery; otherwise, the patients were categorized as cN1 patients. The Institutional Review Board of Wenzhou Medical University approved the present study, and written informed consent was obtained from all patients included.
DNA extraction and BRAF mutation analysis. Genomic DNA was isolated from formalin-fixed paraffin-embedded 7-µm tissue sections using a QIAamp DNA FFPE Tissue kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol. BRAF exon 15 was amplified via polymerase chain reaction (PCR) with the following primers: Forward, 5'-TCA TAA TGC TTG CTC TGA TAG GA-3' and reverse, 5'-GGC CAA AAA TTT AAT CAG TGG A-3'. A 3-µl sample of the DNA template was added into a 50 µl (total volume) reaction containing 25 µl 2X PCR Reagent (containing 0.1 U/µl Taq polymerase, 500 µM dNTP each, 20 mM Tris-HCl, 100 mM KCl, 3 mM MgCl 2 ), 2 µl of each primer, and 18 µl dH 2 O (all Tiangen Biotech Co., Ltd., Beijing, China). The PCR conditions were 94˚C for 3 min, followed by 35 cycles of 94˚C for 30 sec, 55˚C for 30 sec, 72˚C for 1 min and 72˚C for 5 min. The quality of the PCR products was confirmed by 2% agarose gel electrophoresis. Each test was repeated in triplicate, with dH 2 O used as the negative control. The PCR products were sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, USA) on an ABI PRISM 3730XL DNA Analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) to identify the mutation.
Statistical analysis. Statistical analysis was performed using IBM SPSS software (version 19.0; IBM Corp., Armonk, NY, USA). A univariate analysis was conducted to reveal the risk factors associated with central LNM in different histological subtypes of PTC. Factors that demonstrated significant differences were further tested through multivariate analysis. Data were described as the number of cases for categorical variables. Confrontations between different groups were performed using a χ 2 test. When the sample size was <40 or with a theoretical frequency of <1, Fisher's exact test was used instead. For continuous variables, data were described as the mean ± standard deviation. A multivariate analysis was performed using binary logistic regression. The results were presented as odds ratios (ORs) with 95% confidence intervals (CIs). P<0.05 was considered to indicate a statistically significant difference.
Results
Patient clinicopathological characteristics.
A total of 287 patients with PTC were included in the present study. Patient ages ranged between 9 and 77 years, with a mean of 43.82±11.96 years. The female-to-male ratio was 4.86 (49 males vs. 238 females). A total of 1,985 lymph nodes from the central compartment were dissected, among which 837 were identified as cancer metastases by pathologists (2.9 metastatic lymph nodes to 6.9 total lymph nodes dissected from each patient on average). Central LNM was identified in 189 patients (65.85%), and underlying Hashimoto's thyroiditis was identified in 112 patients (39.02%). Other characteristics such as multifocality, extrathyroidal extension and thyroid capsular invasion were identified in 85 (29.62%), 87 (30.31%) and 109 (37.98%) patients, respectively. Among the patients, 172 (59.93%) were patients with cN0 PTC, whereas the other 115 (40.07%) were patients with cN1 PTC. According to the histological subtype classification, 177 (61.67%) and 94 (32.75%) patients were diagnosed with CVPTC and FVPTC, respectively. The remaining 16 patients (5.57%) were grouped under AVPTC, which included tall cell, diffuse sclerosing and poorly differentiated PTC subtypes.
Distribution of central LNM and BRAF
V600E . Among the patients with cN0 PTC, LNM could be identified in 63 patients (58.88%) in the CVPTC group, 21 patients (35.00%) in the FVPTC group and 3 patients (60.00%) in the AVPTC group; the proportion in the cN1 group was 64 (91.43%), 29 (85.29%) and 9 (81.82%) patients in the CVPTC, FVPTC and AVPTC groups, respectively (Fig. 1A and B) . Similarly, among all patients with cN0 PTC, BRAF V600E was detected in 68 patients (63.55%) in the CVPTC group, 29 patients (48.33%) in the FVPTC group and all 5 patients (100.00%) in the AVPTC group; the proportion in the cN1 group was 46 (65.71%), 15 (44.12%) and 8 (72.72%) patients in the CVPTC, FVPTC, and AVPTC groups, respectively ( Fig. 1C and D Univariate analyses V600E was identified to be an independent risk factor for central LNM (P=0.032), with an OR value of 2.586 (95% CI, 1.087-6.151), and underlying Hashimoto's thyroiditis was an independent negative factor in this cohort (P=0.042), with an OR value of 0.411 (95% CI, 0.174-0.970).
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Univariate and multivariate analyses of patients with FVPTC.
The aforementioned factors were analyzed in a total of 94 patients with FVPTC (Table VII) , which comprised 34 patients with cN1 FVPTC (Table VIII) and 60 patients with cN0 FVPTC (Table IX) . However, central LNM was Univariate and multivariate analyses of patients with AVPTC. Given that the patient number in this cohort was limited to 12 and 4 patients in the central LNM-positive and -negative groups, respectively, the risk factors were analyzed in all patients with AVPTC together (Table X) 
Discussion
Risk factors associated with central LNM in patients with PTC have been widely studied; tumor size, extrathyroidal extension, thyroid capsular invasion, underlying Hashimoto's thyroiditis and BRAF V600E have been reported to be associated with LNM (26) (27) (28) . BRAF V600E has been demonstrated to be a good risk factor for cervical LNM and was significantly correlated with recurrence (18, 19) . Nevertheless, certain studies have revealed no correlation between BRAF V600E and cervical LNM (29,30). 
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Total, n +, n (%) -, n (%) P-value OR (95% CI) P-value PTC is composed of several distinct histological subtypes, including CVPTC, FVPTC and AVPTC; AVPTC includes tall cell PTC, diffuse sclerosing PTC and poorly differentiated PTC, which all exhibit more aggressive biological behavior (19) . In the present study, 287 patients with PTC, comprising 177 patients with CVPTC, 94 patients with FVPTC and 16 patients with AVPTC, were analyzed. Multivariate regression analysis revealed that BRAF V600E was independently associated with central LNM in the overall PTC group, which is in accordance with previous reports (18, 19) . However, similar results cannot be drawn from FVPTC or AVPTC, as the BRAF mutation rate was not significantly different between these two PTC subtypes. Importantly, BRAF V600E in CVPTC, which is the most common subtype, was a potent independent indicator for central LNM in addition to the overall PTC group. FVPTC presented some similarities with follicular thyroid carcinoma, and BRAF V600E exhibited a relatively low prevalence in this PTC subtype (31) . The results from the present study are in agreement with studies by Walts et al (32) and Li et al (33) , which stated that BRAF V600E was not associated with LNM in FVPTC. The difference in BRAF V600E mutation rate was not significant in patients with AVPTC who had a high incidence of BRAF V600E between LNM-positive (83.33%) and -negative (75.00%) groups. The significance of the association between BRAF V600E and LNM in AVPTC may be concealed by such a high rate of BRAF V600E . As a consequence, BRAF mutation may perform differently in diverse subtypes. Thus, the divergence in the association between BRAF mutation and central LNM in previous studies may be a result of the different histological subtypes of PTC.
Although previous studies have demonstrated that cervical LNM is associated with local recurrence and even disease-specific survival in patients with PTC (7,34), prophylactic central LND in patients with cN0 PTC remains controversial in thyroid cancer surgery. In the systematic review by Mulla and Schulte (35) , cancerous lymph nodes were detected in 46.15% of 1,946 patients with cN0 PTC. Therefore, Mulla and Schulte (35) advocated for prophylactic central LND to be performed on patients with PTC. By contrast, a previous study by Conzo et al (15) of 752 patients with cN0 PTC revealed a greater rate of surgical complications, including permanent hypoparathyroidism (3.6 vs. 1%; P=0.018) and temporary unilateral vocal cord palsy (3.5% vs. 1.2; P=0.039). Therefore, Conzo et al (15) stated that prophylactic central LND in patients with cN0 PTC should be used selectively.
To improve the pertinence of prophylactic central LND in patients with cN0 PTC and to avoid potential surgical morbidity, the data was further analyzed based on preoperative central lymph node status; the analyses were performed separately for patients with cN0 and cN1 PTC. Univariate analysis of all patients with PTC revealed that BRAF V600E was associated with central LNM in the 115 patients with cN1 PTC and the 172 patients with cN0 PTC. However, in the multivariate regression analysis, BRAF V600E was significant in neither patients with cN0 PTC nor in patients with cN1 PTC, suggesting that the effect of BRAF V600E as an indicator for performing prophylactic central LND was limited in this cohort of patients.
When the patients were subdivided into variant histological subtypes, in the univariate analysis BRAF V600E was a potent indicator for central LNM in patients with CVPTC, in addition to patients with cN0 CVPTC, but not for cN1 patients of this variant. In the multivariate regression, BRAF V600E was independently correlated with central LNM in all patients with CVPTC and patients with cN0 CVPTC, but not in cN1 patients of this subtype.
The aforementioned research demonstrating a correlation between BRAF V600E and central LNM (26) (27) (28) may not be representative of all patients with PTC. As demonstrated in the present study, BRAF V600E was independently associated with central LNM in overall patients with PTC, but when subdivided by histological variant, BRAF V600E was only significantly associated with the CVPTC subtype. In addition, when categorized by preoperative central lymph node status, BRAF V600E was only independently associated with central LNM in patients with cN0 CVPTC instead of in all patients with cN0 PTC. For patients with cN1 CVPTC, suspected LNM was already detected on preoperative ultrasonography and surgical removal of regional lymph nodes was typically recommended, thus the clinical significance of BRAF V600E or other clinicopathological features was limited. As a consequence, BRAF V600E was only associated with central LNM in a selected cohort of patients instead of all patients with PTC.
Other clinicopathological factors have been associated with central LNM. Tumor size has been demonstrated to be an important risk factor for central LNM in numerous studies (28, 33) . In the present study, tumor size was significantly different between central LNM-positive or -negative patients in overall patients with PTC and patients with CVPTC, in addition to in the univariate analysis. Furthermore, tumor size was an independent factor in the multivariate analysis. Upon further investigation using surgical approaches, tumor size was revealed to be associated with central LNM in overall patients with cN0 PTC and in patients with cN0 CVPTC, and was the only independent risk factor associated with central LNM in overall patients with cN0 PTC. Additionally, no significant differences were identified between patients with FVPTC and patients with AVPTC with or without LNM. Thyroid capsular invasion is another widely investigated risk factor for central LNM (26, 27) . The data from the present study demonstrated that thyroid capsular invasion was associated with central LNM in a number of comparison groups, as revealed by the univariate analysis results. Thyroid capsular invasion was the only significantly different factor for central LNM in patients with cN1 CVPTC.
Previous studies have demonstrated that underlying Hashimoto's thyroiditis has a protective effect for patients with PTC, and that it is associated with smaller tumor size, fewer LNM and improved prognosis (36, 37) . The data from the present study demonstrated that underlying Hashimoto's thyroiditis was negatively correlated with central LNM in overall patients with PTC and patients with CVPTC. When further analyzed, the difference was only significant in overall patients with cN0 PTC and in patients with cN0 CVPTC. Underlying Hashimoto's thyroiditis serves as an independent factor only in patients with cN0 CVPTC. Considering that a great fraction of patients with cN1 who received therapeutic LND had central LNM, the suspected regional lymph nodes should be routinely removed. Aggressive features, including larger tumor size, multifocality, extrathyroidal extension, thyroid capsular invasion and BRAF V600E became less important under such a high ratio of central LNM.
The present study has certain limitations. The sample size was not big enough, particularly for patients with s; only 16 patients with AVPTC in total were analyzed in the present study, which may affect the statistics. Additionally, on account of insufficient numbers of patients, the analyses of patients with cN0 and cN1 AVPTC were not performed separately. The association between BRAF V600E and other risk factors with long-term follow-up data in different subgroups require further investigation in order to unveil their prognostic function in different histological subtypes and preoperative central lymph node statuses.
In conclusion, the clinical significance of BRAF V600E for central LNM depends not only on PTC histological subtype, but also on preoperative central lymph node status, with the greatest significance in patients with cN0 CVPTC instead of all patients with PTC. Furthermore, BRAF V600E alone may not be able to accurately indicate the central lymph node status. Hence, other associated factors should also be recognized. 
